Life Cycle Investment Partners’s BeOne Medicines Ltd ONC Stock Holding History

Life Cycle Investment Partners’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20.8M	Buy	+73,048	New	+$21.5M	0.1%	127

Other funds holding ONC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Life Cycle Investment Partners's ONC Position: Q2 2026 in Review

Life Cycle Investment Partners opened a new position in BeOne Medicines Ltd (ONC) in Q2 2026: 73,048 shares worth $20.8M. The stake represents 0.1% of the portfolio and ranks #127 among its holdings.

282 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

Life Cycle Investment Partners held 73,048 shares of BeOne Medicines Ltd worth $20.8M as of Q2 2026.
BeOne Medicines Ltd was a new Life Cycle Investment Partners position in Q2 2026.
BeOne Medicines Ltd made up 0.1% of Life Cycle Investment Partners's portfolio in Q2 2026, its #127 holding.
282 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on Life Cycle Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.